Lenvatinib + Pembrolizumab + Docetaxel + Capecitabine + Paclitaxel + Cetuximab + Lenvatinib
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Squamous Cell Carcinoma of Head and Neck
Conditions
Squamous Cell Carcinoma of Head and Neck
Trial Timeline
Aug 6, 2020 → Oct 30, 2025
NCT ID
NCT04428151About Lenvatinib + Pembrolizumab + Docetaxel + Capecitabine + Paclitaxel + Cetuximab + Lenvatinib
Lenvatinib + Pembrolizumab + Docetaxel + Capecitabine + Paclitaxel + Cetuximab + Lenvatinib is a phase 2 stage product being developed by Eisai for Squamous Cell Carcinoma of Head and Neck. The current trial status is completed. This product is registered under clinical trial identifier NCT04428151. Target conditions include Squamous Cell Carcinoma of Head and Neck.
What happened to similar drugs?
4 of 20 similar drugs in Squamous Cell Carcinoma of Head and Neck were approved
Approved (4) Terminated (2) Active (14)
🔄Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04428151 | Phase 2 | Completed |
Competing Products
20 competing products in Squamous Cell Carcinoma of Head and Neck